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BSTRACT
 
Multiple cytokines play a critical role in orchestrating
and perpetuating inflammation in asthma and several
specific cytokine and chemokine inhibitors are now in
development as future therapy. Anti-interleukin (IL)-5
antibodies markedly reduce peripheral blood and
airway eosinophils, but do not appear to be effective in
symptomatic asthma. Inhibition of IL-4, despite prom-
ising early results in asthma, has been discontinued
and blocking IL-13 may be more effective. Inhibitory
cytokines, such as IL-10, interferons and IL-12 are less
promising, because systemic delivery produces side-
effects. Inhibition of tumor necrosis factor (TNF)-
 
α
 
 may
be useful in severe asthma. Many chemokines are
involved in the inflammatory response of asthma and
several small molecule inhibitors of chemokine recep-
tors are in development. The CCR3 antagonists (which
block eosinophil chemotaxis) are in clinical develop-
ment for asthma. Because so many cytokines are
involved in asthma, drugs that inhibit the synthesis of
multiple cytokines may prove to be more useful; several
such classes of drug are now in clinical development
and any risk of side-effects with these non-specific
inhibitors may be reduced by the inhaled route.
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NTRODUCTION
 
Cytokines play a critical role in the orchestration of
chronic inflammation in all diseases, including asthma.
Multiple cytokines and chemokines have been impli-
cated in the pathophysiology of asthma.
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 There is now
an intensive search for more specific therapies in
asthma. Inhibitors of cytokines and chemokines figure
prominently in these novel therapeutic approaches
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(Table 1).
 
S
 
TRATEGIES
 
 
 
FOR
 
 
 
INHIBITING
 
 
 
CYTOKINES
 
There are several possible approaches to inhibiting
specific cytokines. These range from drugs that inhibit
cytokine synthesis (glucocorticoids, cyclosporine A,
tacrolimus, rapamycin, mycophenolate, T helper 2
(Th2)-selective inhibitors), humanized blocking anti-
bodies to cytokines or their receptors, soluble receptors
to mop up secreted cytokines, small molecule receptor
antagonists or drugs that block the signal transduction
pathways activated by cytokine receptors. In contrast,
there are cytokines that themselves suppress the allergic
inflammatory process and these may have therapeutic
potential in asthma.
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NHIBITION
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CYTOKINES
 
The Th2 lymphocytes play a key role in orchestrating the
eosinophilic inflammatory response in asthma, suggest-
ing that blocking the release or effects of these cytokines
may have therapeutic potential. This has been strongly
supported by studies in experimental animals, including
mice with deletion of the specific Th2 cytokine genes.
 
Anti-interleukin-5
 
Interleukin (IL)-5 plays an essential role in orchestrating
the eosinophilic inflammation of asthma.
 
4
 
 In IL-5 gene
knock-out mice, the eosinophilic response to allergen
and the subsequent airway hyperresponsiveness (AHR)
are markedly suppressed and yet animals have a normal
survival, validating the strategy to inhibit IL-5. This has
also been achieved using blocking antibodies to IL-5.
 
Correspondence: Professor PJ Barnes, Department of Thoracic
Medicine, National Heart and Lung Institute, Imperial College,
Dovehouse Street, London SW3 6LY, UK.
Email: p.j.barnes@ic.ac.uk
Received 18 February 2003.
54 PJ BARNES
Blocking antibodies to IL-5 inhibit eosinophilic inflam-
mation and AHR in animal models of asthma, including
primates.5 This blocking effect may last for up to
3 months after a single intravenous injection of antibody
in primates, making treatment of chronic asthma with
such a therapy a feasible proposition. Humanized mono-
clonal antibodies to IL-5 have been developed and a
single intravenous infusion of one of these antibodies
(mepolizulab) markedly reduces blood eosinophils for
several weeks and prevents eosinophil recruitment into
the airways after allergen challenge in patients with mild
asthma6 (Fig. 1). However, this treatment has no signifi-
cant effect on the early or late response to allergen
challenge or on baseline AHR, suggesting that eosin-
ophils may not be of critical importance for these
responses in humans (Fig. 2). A clinical study in patients
with moderate to severe asthma who had not been
controlled on inhaled corticosteroid therapy confirmed a
Table 1 Cytokine modulators for asthma
Anti-cytokines Inhibitory cytokines Chemokine inhibitors Cytokine synthesis inhibitors
Anti-IL-5 IL-1 receptor antagonist CCR3 antagonists Corticosteroids
Anti-IL-4 IL-10 CCR2 antagonists Immunomodulators
Anti-IL-13 IL-12 CCR4 antagonists Phosphodiesterase-4 inhibitors
Anti-IL-9 Interferons (IFN-α
 
, IFN-γ
 
) CCR8 antagonists NF-κ
 
B inhibitors (IKK2 inhibitors)
Anti-IL-25 IL-18 CXCR2 antagonists p38 MAPK inhibitors
Anti-IL-1 IL-23 CXCR4 antagonists
Anti-TNF-α
IL, interleukin; TNF-α
 
, tumor necrosis factor-α
 
; IFN, interferon; NF-κ
 
B, nuclear factor-κ
 
B; IKK, inhibitor of NF-κ
 
B kinase; MAPK, mitogen-
activated protein kinase.
Fig. 1 Effect of a humanized monoclonal antibody against interleukin-5 (mepolizumab) on circulating eosinophils in patients with
mild asthma, demonstrating a profound and very prolonged inhibitory effect. (
 

 
), placebo (n = 8); ( ), 2.5 mg/kg mepolizumab
(n = 8); (), 10 mg/kg mepolizumab (n = 8). B/L, baseline; D, day; Wk, week. Adapted from Leckie et al.6
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profound reduction in circulating eosinophils, but no
significant improvement in either asthma symptoms or
lung function.7 In both these studies, it would be
expected that high doses of corticosteroids would
improve these functional parameters.6,7 These surprising
results question the critical role of eosinophils in asthma
and indicate that other strategies aimed at inhibiting
eosinophilic inflammation may not be effective. More
recently, a biopsy study has demonstrated that anti-IL-5
antibody, while profoundly reducing eosinophils in the
circulation (by over 95%), is less effective at reducing
eosinophils in bronchial biopsies (by approximately
50%), which may explain why this treatment is not
clinically effective.8 Nevertheless, this suggests that
blocking IL-5 is not likely to be a useful approach to
asthma therapy.
Somewhat similar findings have been reported previ-
ously in some studies in mice, where anti-IL-5 antibodies
reduced eosinophilic responses to allergen, but not AHR,
whereas AHR was reduced by anti-CD4 antibody, which
depletes Th cells9 and suggests that T cell-derived
cytokines other than IL-5 must be playing a more impor-
tant role in AHR.
Non-peptidic IL-5 receptor antagonists would be an
alternative strategy and there is a search for such com-
pounds using molecular modeling of the IL-5 receptor
α-chain and through large-scale throughput screening.
One such molecule, YM-90709, appears to be a rela-
tively selective inhibitor of IL-5-receptors.10 However, the
lack of clinical benefit of anti-IL-5 antibodies has made
this a less attractive approach. It is possible that eosin-
ophils are associated with more chronic aspects of
asthma, such as airway remodeling, and, in mice, a
blocking anti-IL-5 antibody prevents the increased colla-
gen deposition in airways associated with repeated aller-
gen exposure.
Anti-IL-4
Interleukin-4 is critical for the synthesis of IgE by
B lymphocytes and is also involved in eosinophil recruit-
ment to the airways.11 A unique function of IL-4 is
to promote differentiation of Th2 cells and, there-
fore, it acts at a proximal and critical site in the allergic
response, making IL-4 an attractive target for inhibition.
Interleukin-4 blocking antibodies inhibit allergen-
induced AHR, goblet cell metaplasia and pulmonary
eosinophilia in a murine model.11 Therefore, inhibition of
IL-4 may be effective in inhibiting allergic diseases and
soluble humanized IL-4 receptors (sIL-4R) have been
tested in clinical trials. A single nebulized dose of sIL-4R
prevents the fall in lung function induced by withdrawal of
Fig. 2 Effect of a humanized monoclonal antibody against interleukin (IL)-5 (mepomizulab) on (a) the early and late response
to allergen (–––, IL-5 antibody; -----, placebo) and (b) airway hyperresponsiveness (
 

 
, placebo; 
 

 
, IL-5 antibody). FEV1, forced
expiratory volume in 1 s. Adapted from Leckie et al.6
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inhaled corticosteroids in patients with moderately severe
asthma.
 
12
 
 Subsequent studies have demonstrated that
weekly nebulization of sIL-4R improves asthma control
over a 12 week period.
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 However, subsequent studies
in patients with milder asthma proved disappointing
and this treatment has now been withdrawn. Another
approach is blockade of IL-4 receptors with a mutated
form of IL-4 (BAY 36-1677), which binds to and blocks
IL-4R
 
α
 
 and IL-13R
 
α
 
1, thus blocking both IL-4 and
IL-13.
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 This treatment has also been withdrawn.
Interleukin-4 and the closely related cytokine IL-13
signal through a shared surface receptor, namely IL-4R
 
α
 
,
which activates a specific transcription factor, signal
transducers and activators of transcription (STAT)-6.
 
15
 
Deletion of the STAT-6 gene has a similar effect to IL-4
gene knock-out. This has led to a search for inhibitors of
STAT-6 and, although peptide inhibitors that interfere
with the interaction between STAT-6 and Janus kinase
(JAK) linked to IL-4R
 
α
 
 have been discovered, it will be
difficult to deliver these intracellularly. An endogenous
inhibitor of STAT, suppressor of cytokine signaling
(SOCS-1), is a potent inhibitor of IL-4 signaling pathways
and offers a new therapeutic target.
 
15
 
Anti-IL-13
 
There is increasing evidence that IL-13 in mice mimics
many of the features of asthma, including AHR, mucus
hypersecretion and airway fibrosis, independently of
eosinophilic inflammation.
 
16
 
 It potently induces the
secretion of eotaxin from airway epithelial cells and
transforms airway epithelium into a secretory phenotype.
Knocking out the IL-13, but not the IL-4, gene in mice
prevents the development of AHR after allergen, despite
a vigorous eosinophilic response, and the increase in
AHR induced by IL-13 is only seen when the expression
of STAT-6 is lost in airway epithelial cells.
 
16
 
 Interleukin-
13 signals through the IL-4R
 
α
 
, but may also activate
different intracellular pathways via activation of IL-
13R
 
α
 
1,
 
15
 
 so that it may be an important target for the
development of new therapies. A second specific IL-13
receptor, IL-13R
 
α
 
2, exists in soluble form and has a high
affinity for IL-13, thus acting as a decoy receptor for
secreted IL-13. Soluble IL-13R
 
α
 
2 is effective in blocking
the actions of IL-13, including IgE generation, pulmo-
nary eosinophilia and AHR in mice.
 
17
 
 In the murine
model, IL-13R
 
α
 
2 is more effective than IL-4-blocking
antibodies,
 
16
 
 highlighting the potential importance of
IL-13 as a mediator of allergic inflammation. Blocking
IL-13 may be more important in established asthma,
where concentrations of IL-13 are much higher than
those of IL-4. Humanized IL-13R
 
α
 
2 is now in clinical
development as a therapeutic approach for asthma.
 
Anti-IL-9
 
Interleukin-9 is a Th2 cytokine that may enhance
Th2-driven inflammation and amplify mast cell mediator
release and IgE production.
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 Interleukin-9 may also
enhance mucus hypersecretion. Interleukin-9 and its
receptors show an increased expression in asthmatic
airways.
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 A blocking antibody to IL-9 inhibits airway
inflammation and AHR in a murine model of asthma.
 
20
 
Strategies to block IL-9, including blocking humanized
antibodies, are now in development.
 
21
 
Anti-IL-25
 
Interleukin-25 is a newly described cytokine that stimu-
lates the release of Th2 cytokines IL4, IL-5 and IL-13,
suggesting that it may play a role in allergic inflam-
mation.
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 It is released from mast cells via an IgE-
dependent mechanism and is, therefore, a possible
target for inhibition in the treatment of asthma.
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INFLAMMATORY
 
 
 
CYTOKINES
 
Pro-inflammatory cytokines, particularly IL-1
 
β
 
 and tumor
necrosis factor (TNF)-
 
α
 
, may amplify the inflammatory
response in asthma and may be linked to disease
severity. This suggests that blocking IL-1
 
β
 
 or TNF-
 
α
 
 may
have beneficial effects, particularly in severe airway
disease.
 
Anti-IL-1
 
Interleukin-1 expression is increased in asthmatic
airways
 
24
 
 and activates many inflammatory genes that
are expressed in asthma. There are no small molecule
inhibitors of IL-1, but a naturally occurring cytokine, the
IL-1 receptor antagonist (IL-1ra), binds to IL-1 receptors
to block the effects of IL-1. In experimental animals
IL-1ra reduces AHR induced by allergen. However,
human recombinant IL-1ra does not appear to be
effective in the treatment of asthma.
 
25
 
Anti-TNF
 
Tumor necrosis factor-
 
α
 
 is expressed in asthmatic
airways and may play a key role in amplifying asthmatic
inflammation, through the activation of nuclear factor
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(NF)-
 
κ
 
B, activating protein (AP)-1 and other transcription
factors.
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 In rheumatoid arthritis and inflammatory bowel
disease, blocking humanized monoclonal antibodies to
TNF-
 
α
 
 (infliximab) and soluble TNF receptors (etaner-
cept) have produced remarkable clinical responses,
even in patients who are relatively unresponsive to
steroids. Such TNF inhibitors are a logical approach
to asthma therapy, particularly in patients with severe
disease, and clinical trials are now underway.
Because of the problems associated with antibody
based therapies that have to be given by injection, there
is a search for small molecule inhibitors of TNF. Tumor
necrosis factor-
 
α
 
-converting enzyme (TACE) is a matrix
metalloproteinase-related enzyme critical for the release
of TNF from the cell surface. Small molecule TACE inhib-
itors are in development as oral TNF inhibitors.
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CYTOKINES
Some cytokines have anti-inflammatory effects in inflam-
mation and, therefore, have therapeutic potential.3
Whereas it may not be feasible or cost-effective to
administer these proteins as long-term therapy, it may be
possible to develop drugs in the future that increase the
release of these endogenous cytokines or activate their
receptors and specific signal transduction pathways.
Interleukin-10
Interleukin-10 is a potent anti-inflammatory cytokine that
inhibits the synthesis of many inflammatory proteins,
including cytokines (TNF-α, granulocyte–macrophage
colony stimulating factor (GM-CSF), IL-5, chemokines)
and inflammatory enzymes (inducible nitric oxide syn-
thase) that are overexpressed in asthma.28 Indeed, there
may be a defect in IL-10 transcription and secretion from
macrophages in asthma, suggesting that IL-10 may be
defective in atopic diseases.29,30 In sensitized animals,
IL-10 is effective in suppressing the inflammatory
response to allergen31 and CD4+ cells engineered to
secrete IL-10 suppress airway inflammation in a murine
model of asthma.32 Specific allergen immunotherapy
results in increased production of IL-10 by Th cells and
this may contribute to the beneficial effects of immuno-
therapy.33
Recombinant human IL-10 has proved to be effective
in controlling inflammatory bowel disease and psoriasis,
where similar cytokines are expressed, and may be given
as a weekly injection.34 Although IL-10 is reasonably well
tolerated, there are hematological side-effects. In the
future, drugs that activate the unique signal transduction
pathways activated by the IL-10 receptor or drugs that
increase endogenous production of IL-10 may be devel-
oped. In mice, drugs that elevate cAMP increase IL-10
production, but this does not appear to be the case in
human cells.35
Interferons
Interferon (IFN)-γ inhibits Th2 cells and should, there-
fore, reduce atopic inflammation. In sensitized animals,
nebulized IFN-γ inhibits eosinophilic inflammation induced
by allergen exposure and adenovirus-mediated gene
transfer of IFN-γ inhibits allergic inflammation in mice.36
However, administration of IFN-γ by nebulization to
asthmatic patients did not significantly reduce eosi-
nophilic inflammation, possibly due to the difficulty in
obtaining a high enough concentration locally in the
airways.37 Interestingly, allergen immunotherapy increases
IFN-γ production by circulating T cells in patients with
clinical benefit38 and increases the numbers of IFN-γ-
expressing cells in nasal biopsies of patients with allergic
rhinitis.39 A preliminary report suggests that IFN-α may
be useful in the treatment of patients with severe asthma
who have reduced responsiveness to corticosteroids.40
Interleukin-12
Interleukin-12 is the endogenous regulator of Th1 cell
development and determines the balance between Th1
and Th2 cells.41 Interleukin-12 administration to rats
inhibits allergen-induced inflammation and inhibits
sensitization to allergens. Interleukin-12 releases IFN-γ,
but has additional effects on T cell differentiation.
Interleukin-12 levels released from whole blood cells are
lower in asthmatic patients, indicating a possible reduc-
tion in IL-12 secretion.42
Recombinant human IL-12 has been administered to
humans and has several toxic effects that are diminished
by slow escalation of the dose.43 In patients with mild
asthma, weekly infusions of human recombinant IL-12 in
escalating doses over 4 weeks caused a progressive fall
in circulating eosinophils and a reduction in the normal
rise in circulating eosinophils after allergen challenge44
(Fig. 3). There was a concomitant reduction in eosin-
ophils in induced sputum. However, there was no reduc-
tion in either the early or late response to inhaled allergen
challenge or any reduction in AHR (as with anti-IL-5
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therapy). Furthermore, most patients suffered from
malaise and one of the 12 subjects had an episode of
cardiac arrhythmia. This suggests that IL-12 is not a suit-
able treatment for asthma. In mice, administration of an
IL-12–allergen fusion protein results in the development
of a specific Th1 response to the allergen, with increased
production of an allergen-specific IgG2, rather than the
normal Th2 response with IgE formation.45 This indicates
the possibility of using local IL-12 together with specific
allergens to provide a more specific immunotherapy,
which may even be curative if applied early in the course
of the atopic disease.
Interleukin-18 and IL-23
Interleukin-18 was originally described as IFN-γ-
releasing factor, but has a different mechanism of action
to IL-12.46 Interleukin-12 and IL-18 appear to have a
synergistic effect on inducing IFN-γ release and for
inhibiting IL-4-dependent IgE production and AHR,47 but
no clinical studies have been reported so far.
Interleukin-23 is structurally related to IL-12 and
shares some of its biological effects, so should have a
protective function in asthma.48 Its clinical potential has
not yet been explored.
CHEMOKINE INHIBITORS
Many chemokines are involved in the recruitment of
inflammatory cells in asthma.49 Over 50 different chem-
okines are now recognized and they activate up to 20
different surface receptors.50 Chemokine receptors
belong to the seven transmembrane receptor super-
family of G-protein-coupled receptors and this makes it
possible to find small molecule inhibitors, which has not
yet been possible for classic cytokine receptors.51 Some
chemokines appear to be selective for single chemok-
ines, whereas others are promiscuous and mediate the
effects of several related chemokines (Fig. 4). Chemok-
ines appear to act in sequence in determining the final
inflammatory response and so inhibitors may be more or
less effective depending on the kinetics of the response.
CCR3 inhibitors
Several chemokines, including eotaxin, eotaxin-2,
eotaxin-3, RANTES and macrophage chemoattractant
protein (MCP)-4, activate a common receptor on eosi-
nophils designated CCR3.52 A neutralizing antibody
against eotaxin reduces eosinophil recruitment into the
lung after allergen and the associated AHR in mice.53
There is increased expression of eotaxin, eotaxin-2,
MCP-3, MCP-4 and CCR3 in the airways of asthmatic
patients and this is correlated with increased AHR.54
Several small molecule inhibitors of CCR3, including
UCB35625, SB-297006 and SB-328437, are effective
in inhibiting eosinophil recruitment in allergen models of
asthma55,56 and drugs in this class are currently under-
going clinical trials in asthma. Although it was thought
that CCR3 were restricted to eosinophils, there is some
evidence for their expression on Th2 cells and mast cells,
so that these inhibitors may have a more widespread
Fig. 3 Effect of interleukin
(IL)-12 on peripheral blood
eosinophils in patients with mild
asthma. (), placebo (n = 20);
( ), IL-12 (n = 19) IL-12 was
given in progressively increasing
doses as an intravenous injec-
tion. Adapted from Bryan et al.44
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effect than on eosinophils alone, making them poten-
tially more valuable in asthma treatment.
RANTES, which shows increased expression in asth-
matic airways, also activates CCR3, but also has effects
on CCR1 and CCR5, which may play a role in T cell
recruitment. Modification of the N-terminal of RANTES
(met-RANTES) has a blocking effect on RANTES by inhib-
iting these receptors.57
CCR2 inhibitors
Macrophage chemoattractant protein-1 activates CCR2
on monocytes and T lymphocytes. Blocking MCP-1 with
neutralizing antibodies reduces recruitment of both T
cells and eosinophils in a murine model of ovalbumin-
induced airway inflammation, with a marked reduction
in AHR.53 Macrophage chemoattractant protein-1 also
recruits and activates mast cells, an effect that is medi-
ated via CCR2. Macrophage chemoattractant protein-1
instilled into the airways induces marked and prolonged
AHR in mice, associated with mast cell degranulation.
A neutralizing antibody to MCP-1 blocks the development
of AHR in response to allergen.58 Macrophage chemo-
attractant protein-1 levels are increased in broncho-
alveolar lavage fluid of patients with asthma.59 This has
led to a search for small molecule inhibitors of CCR2.
Other CCR inhibitors
CCR4 and CCR8 are selectively expressed on Th2 cells
and are activated by the chemokines monocyte-derived
chemokine (MDC) and thymus and activation-dependent
chemokine (TARC).60 Therefore, inhibitors of CCR4 and
CCR8 may inhibit the recruitment of Th2 cells and, thus,
persistent eosinophilic inflammation in the airways.
CCR8 gene deletion does not have any effects on
allergic inflammation in mice, suggesting that this recep-
tor may not be an effective target.61 In addition, CXC
receptor (CXCR) 4 is selectively expressed on Th2 cells
and a small molecule inhibitor (AMD3100) inhibits
allergen-induced inflammation in a murine model of
asthma.62
Fig. 4 Chemokine receptor antagonists in asthma. Several chemokines are likely to be involved in the pathophysiology of asthma.
There are three major chemokine receptor targets in asthma: CCR3, which is most advanced in terms of small molecule inhibitor
development, but also CCR2, CCR4/8, and CXCR4, for which small molecule inhibitors are now in development. MCP, macro-
phage chemoattractant protein; MDC, monocyte-derived chemokine; TARC, thymus and activation-dependent chemokine.
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CCR7 plays a role in the migration of dendritic cells to
regional lymph nodes and, therefore, blocking this recep-
tor may suppress antigen presentation.63
CXCR inhibitors
CXC receptors mediate the effects of CXC chemokines,
which act predominantly on neutrophils and monocytes.
Neutrophils are not a prominent feature of inflammation
in patients with chronic asthma and inflammation is
dominated by eosinophils. However, there is evidence
for increased neutrophils in biopsies and induced
sputum of patients with severe asthma who are treated
with high doses of inhaled or oral corticosteroids, and
the levels of IL-8 are increased.64,65 It is not certain
whether this neutrophilic inflammation contributes to
pathophysiology, but it is possible that CXCR2 inhibitors
may have a therapeutic role in severe asthma.
OTHER APPROACHES TO CYTOKINE INHIBITION
Although there have been several attempts to block
specific cytokines, this may not be adequate to block
chronic inflammation in asthma, because so many
cytokines are involved and there is considerable redun-
dancy of effects. This has suggested that the develop-
ment of drugs that have a more general effect on
cytokine synthesis may be more successful. However,
these drugs also affect other inflammatory processes, so
their beneficial effects cannot necessarily be ascribed to
inhibition of cytokine synthesis alone.
Corticosteroids
Corticosteroids are, by far, the most effective treatments
for asthma and part of their efficacy is due to inhibition
of inflammatory cytokine expression. This is mediated via
an effect on glucocorticoid receptors to reverse the
acetylation of core histones, which is linked to increased
expression of inflammatory genes, such as those encod-
ing cytokines and chemokines.66
Immunomodulatory drugs
Cyclosporine A, tacrolimus and rapamycin inhibit the
transcription factor nuclear factor of activated T cells
(NF-AT), which regulates the secretion of IL-2, IL-4, IL-5,
IL-13 and GM-CSF by T lymphocytes.67 Although it has
some reported beneficial steroid-sparing effects in asthma,
the toxicity of cyclosporine A limits its usefulness, at least
when given orally. More selective Th2 selective drugs
may be safer for the treatment of asthma in the future.
An inhibitor of Th2 cytokines, namely suplatast tosilate,68
provides clinical benefit in asthma.69
Phosphodiesterase 4 inhibitors
Phosphodiesterase (PDE) 4 inhibitors inhibit the release
of cytokines and chemokines from inflammatory cells via
an increase in intracellular cAMP.70 Their clinical use is
limited in asthma by side-effects, such as nausea. In
contrast with corticosteroids, PDE4 inhibitors have a
potent inhibitory effect on neutrophils, indicating that
they may be useful anti-inflammatory treatments in more
severe asthma.
Nuclear factor-κB inhibitors
Nuclear factor-κB regulates the expression of many
cytokines and chemokines involved in asthma.71 There
are several possible approaches to inhibition of NF-κB,
including gene transfer of the inhibitor of NF-κB (IκB),
inhibitors of IκB kinase-2 (IKK2), NF-κB-inducing kinase
(NIK) and IκB ubiquitin ligase, which regulate the activity
of NF-κB, and the development of drugs that inhibit the
degradation of IκB.72 One concern about this approach
is that effective inhibitors of NF-κB may result in immune
suppression and impair host defences, because knock-
out mice that lack NF-κB proteins succumb to septi-
cemia.72 However, there are alternative pathways of
NF-κB activation that may be more important in inflam-
matory disease. Several small molecule inhibitors of
IKK2 are now in development.
P38 mitogen-activated protein kinase 
inhibitors
Mitogen-activated protein kinases (MAPK) play a key
role in chronic inflammation and several complex
enzyme cascades have now been defined. One of these,
the p38 MAPK pathway, is involved in the expression of
inflammatory cytokines and chemokines.73 Small mole-
cule inhibitors of p38 MAPK, such as SB 203580,
SB 239063 and RWJ 67657, also known as cytokine
synthesis anti-inflammatory drugs (CSAIDS), have now
been developed and these drugs have a broad range
of anti-inflammatory effects.74 There may be issues of
safety, because p38 MAPK are involved in host defence.
However, it is possible that the inhaled route of delivery
may reduce the risk of side-effects.
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CONCLUSIONS
There are several specific cytokine and chemokine
inhibitors now in development for the treatment of
asthma. Inhibition of IL-4 with sIL-4R in asthma showed
promising early results, but this was not confirmed in
larger trials and IL-13 inhibition is more promising. Anti-
IL-5 antibody is very effective at inhibiting peripheral
blood and airway eosinophils, but does not appear to
be effective in symptomatic asthma. Inhibitory cytokines,
such as IL-10, interferons and IL-12, are less promising,
because systemic delivery produces side-effects and it
may be necessary to develop inhaled delivery systems.
Inhibition of TNF-α may be useful in the treatment of
severe asthma. Many chemokines are involved in the
inflammatory response of asthma and small molecule
inhibitors of chemokine receptors are now in develop-
ment. The CCR3 antagonists are now being developed
for the treatment of asthma. Because so many cytokines
are involved in these complex diseases, drugs that inhibit
the synthesis of multiple cytokines may be more success-
ful. Several such classes of drug are now in clinical
development, including PDE4, p38 MAPK and IKK2
inhibitors. The risk of side-effects in these non-specific
inhibitors may be reduced by an inhaled route of
delivery.
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